JFG
APLS

Jefferies Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Jefferies Financial Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-219,000
Closed -$8.81M – 1651
2026
Q1 		$8.81M Buy
219,000
+210,282
+2,412% +$4.53M 0.06% 226
2025
Q4 		$219K Sell
8,718
-242,837
-97% -$5.7M ﹤0.01% 1591
2025
Q3 		$5.69M Sell
251,555
-326,650
-56% -$7.62M 0.03% 336
2025
Q2 		$10M Sell
578,205
-21,050
-4% -$390K 0.08% 175
2025
Q1 		$13.1M Buy
599,255
+257,894
+76% +$7.12M 0.12% 119
2024
Q4 		$10.9M Buy
341,361
+292,850
+604% +$8.81M 0.07% 210
2024
Q3 		$1.4M Buy
48,511
+47,875
+7,528% +$1.77M 0.01% 690
2024
Q2 		$24.4K Hold
636
– – ﹤0.01% 1343
2024
Q1 		$37.4K Sell
636
-21,908
-97% -$1.4M ﹤0.01% 1502
2023
Q4 		$1.35M Buy
22,544
+18,236
+423% +$925K 0.01% 849
2023
Q3 		$164K Sell
4,308
-12,892
-75% -$566K ﹤0.01% 1379
2023
Q2 		$1.57M Buy
17,200
+14,725
+595% +$1.27M 0.01% 748
2023
Q1 		$163K Buy
+2,475
New +$143K ﹤0.01% 1383

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jefferies Financial Group's APLS Position: Q2 2026 in Review

Jefferies Financial Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 219,000 shares — an estimated $8.81M sold.

Jefferies Financial Group first reported a position in APLS in Q1 2023 and held it in 13 quarters. The position peaked at $13.1M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Jefferies Financial Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 219,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.81M.
  • Jefferies Financial Group first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 13 quarters.
  • Jefferies Financial Group's Apellis Pharmaceuticals position peaked at $13.1M in Q1 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.